A production platform for disulfide-bonded peptides in the periplasm of Escherichia coli.
Aprotinin
CASPON™ tag
Fed-batch cultivation
Parathyroid hormone
Plectasin
Recombinant peptides
Somatostatin
Journal
Microbial cell factories
ISSN: 1475-2859
Titre abrégé: Microb Cell Fact
Pays: England
ID NLM: 101139812
Informations de publication
Date de publication:
05 Jun 2024
05 Jun 2024
Historique:
received:
03
04
2024
accepted:
01
06
2024
medline:
6
6
2024
pubmed:
6
6
2024
entrez:
5
6
2024
Statut:
epublish
Résumé
Recombinant peptide production in Escherichia coli provides a sustainable alternative to environmentally harmful and size-limited chemical synthesis. However, in-vivo production of disulfide-bonded peptides at high yields remains challenging, due to degradation by host proteases/peptidases and the necessity of translocation into the periplasmic space for disulfide bond formation. In this study, we established an expression system for efficient and soluble production of disulfide-bonded peptides in the periplasm of E. coli. We chose model peptides with varying complexity (size, structure, number of disulfide bonds), namely parathyroid hormone 1-84, somatostatin 1-28, plectasin, and bovine pancreatic trypsin inhibitor (aprotinin). All peptides were expressed without and with the N-terminal, low molecular weight CASPON™ tag (4.1 kDa), with the expression cassette being integrated into the host genome. During BioLector™ cultivations at microliter scale, we found that most of our model peptides can only be sufficiently expressed in combination with the CASPON™ tag, otherwise expression was only weak or undetectable on SDS-PAGE. Undesired degradation by host proteases/peptidases was evident even with the CASPON™ tag. Therefore, we investigated whether degradation happened before or after translocation by expressing the peptides in combination with either a co- or post-translational signal sequence. Our results suggest that degradation predominantly happened after the translocation, as degradation fragments appeared to be identical independent of the signal sequence, and expression was not enhanced with the co-translational signal sequence. Lastly, we expressed all CASPON™-tagged peptides in two industry-relevant host strains during C-limited fed-batch cultivations in bioreactors. We found that the process performance was highly dependent on the peptide-host-combination. The titers that were reached varied between 0.6-2.6 g L In this work, we demonstrated the potential of the CASPON™ technology as a highly efficient platform for the production of soluble peptides in the periplasm of E. coli. The titers we show here are unprecedented whenever parathyroid hormone, somatostatin, plectasin or bovine pancreatic trypsin inhibitor were produced in E. coli, thus making our proposed upstream platform favorable over previously published approaches and chemical synthesis.
Sections du résumé
BACKGROUND
BACKGROUND
Recombinant peptide production in Escherichia coli provides a sustainable alternative to environmentally harmful and size-limited chemical synthesis. However, in-vivo production of disulfide-bonded peptides at high yields remains challenging, due to degradation by host proteases/peptidases and the necessity of translocation into the periplasmic space for disulfide bond formation.
RESULTS
RESULTS
In this study, we established an expression system for efficient and soluble production of disulfide-bonded peptides in the periplasm of E. coli. We chose model peptides with varying complexity (size, structure, number of disulfide bonds), namely parathyroid hormone 1-84, somatostatin 1-28, plectasin, and bovine pancreatic trypsin inhibitor (aprotinin). All peptides were expressed without and with the N-terminal, low molecular weight CASPON™ tag (4.1 kDa), with the expression cassette being integrated into the host genome. During BioLector™ cultivations at microliter scale, we found that most of our model peptides can only be sufficiently expressed in combination with the CASPON™ tag, otherwise expression was only weak or undetectable on SDS-PAGE. Undesired degradation by host proteases/peptidases was evident even with the CASPON™ tag. Therefore, we investigated whether degradation happened before or after translocation by expressing the peptides in combination with either a co- or post-translational signal sequence. Our results suggest that degradation predominantly happened after the translocation, as degradation fragments appeared to be identical independent of the signal sequence, and expression was not enhanced with the co-translational signal sequence. Lastly, we expressed all CASPON™-tagged peptides in two industry-relevant host strains during C-limited fed-batch cultivations in bioreactors. We found that the process performance was highly dependent on the peptide-host-combination. The titers that were reached varied between 0.6-2.6 g L
CONCLUSION
CONCLUSIONS
In this work, we demonstrated the potential of the CASPON™ technology as a highly efficient platform for the production of soluble peptides in the periplasm of E. coli. The titers we show here are unprecedented whenever parathyroid hormone, somatostatin, plectasin or bovine pancreatic trypsin inhibitor were produced in E. coli, thus making our proposed upstream platform favorable over previously published approaches and chemical synthesis.
Identifiants
pubmed: 38840157
doi: 10.1186/s12934-024-02446-6
pii: 10.1186/s12934-024-02446-6
doi:
Substances chimiques
Disulfides
0
Peptides
0
Recombinant Proteins
0
Aprotinin
9087-70-1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
166Informations de copyright
© 2024. The Author(s).
Références
Henninot A, Collins JC, Nuss JM. The Current State of Peptide Drug Discovery: Back to the Future? J Med Chem. 2018;61:1382–414.
pubmed: 28737935
doi: 10.1021/acs.jmedchem.7b00318
Wegmüller S, Schmid S. Recombinant peptide production in microbial cells. Curr Org Chem. 2014;18(8):1005–19.
doi: 10.2174/138527281808140616160013
Marqus S, Pirogova E, Piva TJ. Evaluation of the use of therapeutic peptides for cancer treatment. J Biomed Sci. 2017;24(1):1–15.
doi: 10.1186/s12929-017-0328-x
Lien S, Lowman HB. Therapeutic peptides. Trends Biotechnol. 2003;21:556–62.
pubmed: 14624865
doi: 10.1016/j.tibtech.2003.10.005
Lau JL, Dunn MK. Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018;26(10):2700–7.
pubmed: 28720325
doi: 10.1016/j.bmc.2017.06.052
Boohaker JR, Lee WM, Vishnubhotla P, Perez MJL, Khaled RA. The use of therapeutic peptides to target and to kill cancer cells. Curr Med Chem. 2012;19(22):3794–804.
pubmed: 22725698
pmcid: 4537071
doi: 10.2174/092986712801661004
León Madrazo A, Segura Campos MR. Review of antimicrobial peptides as promoters of food safety: limitations and possibilities within the food industry. J Food Saf. 2020;40: e12854.
doi: 10.1111/jfs.12854
Errante F, Ledwoń P, Latajka R, Rovero P, Papini AM. Cosmeceutical peptides in the framework of sustainable wellness economy. Front Chem. 2020;8:969.
doi: 10.3389/fchem.2020.572923
Isidro-Llobet A, Kenworthy MN, Mukherjee S, Kopach ME, Wegner K, Gallou F, et al. Sustainability challenges in peptide synthesis and purification: from R&D to production. J Org Chem. 2019;84(8):4615–28.
pubmed: 30900880
doi: 10.1021/acs.joc.8b03001
Chan WC, White PD. Fmoc solid phase peptide synthesis: a practical apporach. Oxford: Oxford University Press; 2000. p. 1–246.
Laps S, Atamleh F, Kamnesky G, Sun H, Brik A. General synthetic strategy for regioselective ultrafast formation of disulfide bonds in peptides and proteins. Nat Commun. 2021;12(1):1–9.
doi: 10.1038/s41467-021-21209-0
Schmidt FR. Recombinant expression systems in the pharmaceutical industry. Appl Microbiol Biotechnol. 2004;65:363–72.
pubmed: 15480623
doi: 10.1007/s00253-004-1656-9
Schütz A, Bernhard F, Berrow N, Buyel JF, Ferreira-da-Silva F, Haustraete J, et al. A concise guide to choosing suitable gene expression systems for recombinant protein production. STAR Protocols. 2023;4: 102572.
pubmed: 37917580
pmcid: 10643540
doi: 10.1016/j.xpro.2023.102572
Parachin NS, Mulder KC, Viana AAB, Dias SC, Franco OL. Expression systems for heterologous production of antimicrobial peptides. Peptides. 2012;38:446–56.
pubmed: 23022589
doi: 10.1016/j.peptides.2012.09.020
Rosano GL, Morales ES, Ceccarelli EA. New tools for recombinant protein production in Escherichia coli: a 5-year update. Protein Sci. 2019;28:1412–22.
pubmed: 31219641
pmcid: 6635841
doi: 10.1002/pro.3668
Manta B, Boyd D, Berkmen M. Disulfide bond formation in the periplasm of Escherichia coli. EcoSal Plus. 2019.
Mergulhão FJM, Summers DK, Monteiro GA. Recombinant protein secretion in Escherichia coli. Biotechnol Adv. 2005;23(3):177–202.
pubmed: 15763404
doi: 10.1016/j.biotechadv.2004.11.003
Green ER, Mecsas J. Bacterial secretion systems: an overview. Microbiol Spectr. 2016.
Fink M, Schimek C, Cserjan-Puschmann M, Reinisch D, Brocard C, Hahn R, et al. Integrated process development: the key to improve Fab production in E. coli. Biotechnol J. 2021;16(6):2000562.
doi: 10.1002/biot.202000562
Fink M, Vazulka S, Egger E, Jarmer J, Grabherr R, Cserjan-Puschmann M, et al. Microbioreactor cultivations of fab-producing Escherichia coli reveal genome-integrated systems as suitable for prospective studies on direct fab expression effects. Biotechnol J. 2019;14(11):1800637.
doi: 10.1002/biot.201800637
Costa S, Almeida A, Castro A, Domingues L. Fusion tags for protein solubility, purification, and immunogenicity in Escherichia coli: the novel Fh8 system. Front Microbiol. 2014;5:63.
pubmed: 24600443
pmcid: 3928792
doi: 10.3389/fmicb.2014.00063
Lingg N, Cserjan-Puschmann M, Fischer A, Engele P, Kröß C, Schneider R, et al. Advanced purification platform using circularly permuted caspase-2 for affinity fusion-tag removal to produce native fibroblast growth factor 2. J Chem Technol Biotechnol. 2021;96(6):1515–22.
doi: 10.1002/jctb.6666
Köppl C, Lingg N, Fischer A, Kröß C, Loibl J, Buchinger W, et al. Fusion tag design influences soluble recombinant protein production in Escherichia coli. Int J Mol Sci. 2022;23:7678.
pubmed: 35887026
pmcid: 9321918
doi: 10.3390/ijms23147678
Lingg N, Kröß C, Engele P, Öhlknecht C, Köppl C, Fischer A, et al. CASPON platform technology: ultrafast circularly permuted caspase-2 cleaves tagged fusion proteins before all 20 natural amino acids at the N-terminus. N Biotechnol. 2022;71:37–46.
pubmed: 35926774
doi: 10.1016/j.nbt.2022.07.002
Cserjan-Puschmann M, Lingg N, Engele P, Kröß C, Loibl J, Fischer A, et al. Production of circularly permuted caspase-2 for affinity fusion-tag removal: cloning, expression in Escherichia coli, purification, and characterization. Biomolecules. 2020;10(12):1592.
pubmed: 33255244
pmcid: 7760212
doi: 10.3390/biom10121592
Potts JT. Parathyroid hormone: past and present. J Endocrinol. 2005;187:311–25.
pubmed: 16423810
doi: 10.1677/joe.1.06057
O’Toole TJ, Sharma S. Physiology. Somatostatin. StatPearls: StatPearls Publishing; 2023.
Mygind PH, Fischer RL, Schnorr KM, Hansen MT, Sönksen CP, Ludvigsen S, et al. Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. Nature. 2005;437(7061):975–80.
pubmed: 16222292
doi: 10.1038/nature04051
Aprotinin. In: Meyler’s side effects of drugs. Elsevier; 2016. p. 660–7.
Richardson JS. The anatomy and taxonomy of protein structure. Adv Protein Chem. 1981;34(C):167–339.
pubmed: 7020376
doi: 10.1016/S0065-3233(08)60520-3
Wilkins MR, Lindskog I, Gasteiger E, Bairoch A, Sanchez JC, Hochstrasser DF, et al. Detailed peptide characterization using PEPTIDEMASS—a world-wide-web-accessible tool. Electrophoresis. 1997;18:403–8.
pubmed: 9150918
doi: 10.1002/elps.1150180314
Gasteiger E, Gattiker A, Hoogland C, Ivanyi I, Appel RD, Bairoch A. ExPASy: the proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res. 2003;31(13):3784–8.
pubmed: 12824418
pmcid: 168970
doi: 10.1093/nar/gkg563
Stráner P, Taricska N, Szabó M, Tóth KG, Perczel A. Bacterial expression and/or solid phase peptide synthesis of 20–40 amino acid long polypeptides and miniproteins, the case study of Class B GPCR ligands. Curr Protein Pept Sci. 2016;17(2):147–55.
pubmed: 26521952
doi: 10.2174/1389203716666151102105215
Gottesman S, Maurizi MR. Regulation by proteolysis: energy-dependent proteases and their targets. Microbiol Rev. 1992;56(4):592–621.
pubmed: 1480111
pmcid: 372890
doi: 10.1128/mr.56.4.592-621.1992
Kenniston JA, Baker TA, Sauer RT. Partitioning between unfolding and release of native domains during ClpXP degradation determines substrate selectivity and partial processing. Proc Natl Acad Sci U S A. 2005;102(5):1390–5.
pubmed: 15671177
pmcid: 547888
doi: 10.1073/pnas.0409634102
Schmidt R, Bukau B, Mogk A. Principles of general and regulatory proteolysis by AAA+ proteases in Escherichia coli. Res Microbiol. 2009;160(9):629–36.
pubmed: 19781640
doi: 10.1016/j.resmic.2009.08.018
Rozkov A, Enfors SO. Analysis and control of proteolysis of recombinant proteins in Escherichia coli. Adv Biochem Eng Biotechnol. 2004;89:163–95.
pubmed: 15217159
Cornista J, Ikeuchi S, Haruki M, Kohara A, Takano K, Morikawa M, et al. Cleavage of various peptides with pitrilysin from Escherichia coli: kinetic analyses using β-endorphin and its derivatives. Biosci Biotechnol Biochem. 2004;68(10):2128–37.
pubmed: 15502359
doi: 10.1271/bbb.68.2128
Baneyx F, Georgiou G. Construction and characterization of Escherichia coli strains deficient in multiple secreted proteases: protease III degrades high-molecular-weight substrates in vivo. J Bacteriol. 1991;173(8):2696–703.
pubmed: 2013581
pmcid: 207839
doi: 10.1128/jb.173.8.2696-2703.1991
Thompson MW, Maurizi MR. Activity and specificity of Escherichia coli ClpAP protease in cleaving model peptide substrates. J Biol Chem. 1994;269(27):18201–8.
pubmed: 8027081
doi: 10.1016/S0021-9258(17)32435-3
Meltzer M, Hasenbein S, Mamant N, Merdanovic M, Poepsel S, Hauske P, et al. Structure, function and regulation of the conserved serine proteases DegP and DegS of Escherichia coli. Res Microbiol. 2009;160(9):660–6.
pubmed: 19695325
doi: 10.1016/j.resmic.2009.07.012
Kolmar H, Waller PRH, Sauer RT. The DegP and DegQ periplasmic endoproteases of Escherichia coli: specificity for cleavage sites and substrate conformation. J Bacteriol. 1996;178(20):5925–9.
pubmed: 8830688
pmcid: 178448
doi: 10.1128/jb.178.20.5925-5929.1996
Silber KR, Keiler KC, Sauer RT. Tsp: a tail-specific protease that selectively degrades proteins with nonpolar C termini. Proc Natl Acad Sci U S A. 1992;89(1):295–9.
pubmed: 1729701
pmcid: 48223
doi: 10.1073/pnas.89.1.295
Maurizi MR. Proteases and protein degradation in Escherichia coli. Experientia. 1992;48:178–201.
pubmed: 1740190
doi: 10.1007/BF01923511
Glick BR. Metabolic load and heterologous gene expression. Biotechnol Adv. 1995;13(2):247–61.
pubmed: 14537822
doi: 10.1016/0734-9750(95)00004-A
Cranford-Smith T, Huber D. The way is the goal: how SecA transports proteins across the cytoplasmic membrane in bacteria. FEMS Microbiol Lett. 2018;365:93.
doi: 10.1093/femsle/fny093
Gu SQ, Jöckel J, Beinker P, Warnecke J, Semenkov YP, Rodnina MV, et al. Conformation of 4.5S RNA in the signal recognition particle and on the 30S ribosomal subunit. RNA. 2005;11(9):1374–84.
pubmed: 16043501
pmcid: 1370821
doi: 10.1261/rna.7219805
Josefsson LG, Randall LL. Different exported proteins in E. coli show differences in the temporal mode of processing in vivo. Cell. 1981;25(1):151–7.
pubmed: 7023693
doi: 10.1016/0092-8674(81)90239-7
Kleiner-Grote GRM, Risse JM, Friehs K. Secretion of recombinant proteins from E. coli. Eng Life Sci. 2018;18(8):532–50.
pubmed: 32624934
pmcid: 6999260
doi: 10.1002/elsc.201700200
Yen MR, Peabody CR, Partovi SM, Zhai Y, Tseng YH, Saier MH. Protein-translocating outer membrane porins of Gram-negative bacteria. Biochim Biophys Acta. 2002;1562:6–31.
pubmed: 11988218
doi: 10.1016/S0005-2736(02)00359-0
Zhang G, Brokx S, Weiner JH. Extracellular accumulation of recombinant proteins fused to the carrier protein YebF in Escherichia coli. Nat Biotechnol. 2006;24(1):100–4.
pubmed: 16369539
doi: 10.1038/nbt1174
McCarter JD, Stephens D, Shoemaker K, Rosenberg S, Kirsch JF, Georgiou G. Substrate specificity of the Escherichia coli outer membrane protease OmpT. J Bacteriol. 2004;186(17):5919–25.
pubmed: 15317797
pmcid: 516829
doi: 10.1128/JB.186.17.5919-5925.2004
Hwang BY, Varadarajan N, Li H, Rodriguez S, Iverson BL, Georgiou G. Substrate specificity of the Escherichia coli outer membrane protease OmpP. J Bacteriol. 2007;189(2):522–30.
pubmed: 17085556
doi: 10.1128/JB.01493-06
Marisch K, Bayer K, Scharl T, Mairhofer J, Krempl PM, Hummel K, et al. A comparative analysis of industrial Escherichia coli K-12 and B strains in high-glucose batch cultivations on process-, transcriptome- and proteome level. PLoS ONE. 2013;8(8):70516.
doi: 10.1371/journal.pone.0070516
Yoon SH, Han MJ, Jeong H, Lee CH, Xia XX, Lee DH, et al. Comparative multi-omics systems analysis of Escherichia coli strains B and K-12. Genome Biol. 2012;13(5):R37.
pubmed: 22632713
pmcid: 3446290
doi: 10.1186/gb-2012-13-5-r37
Aumelas A, Chiche L, Kubo S, Chino N, Tamaoki H, Kobayashi Y. [Lys(-2)-Arg(-1)]endothelin-1 solution structure by two-dimensional 1H-NMR: possible involvement of electrostatic interactions in native disulfide bridge formation and in biological activity decrease. Biochemistry. 1995;34(14):4546–61.
pubmed: 7718556
doi: 10.1021/bi00014a007
Hidaka Y, Ohno M, Hemmasi B, Hill O, Forssmann WG, Shimonishi Y. In vitro disulfide-coupled folding of guanylyl cyclase-activating peptide and its precursor protein. Biochemistry. 1998;37(23):8498–507.
pubmed: 9622502
doi: 10.1021/bi9731246
Zavodszky M, Chen C, Huang J, Zolkiewski M, Wen L, Krishnamoorthi R. Disulfide bond effects on protein stability: designed variants of Cucurbita maxima trypsin inhibitor-V. Protein Sci. 2001;10(1):149–60.
pubmed: 11266603
pmcid: 2249841
doi: 10.1110/ps.26801
Fu XY, Tong WY, Wei DZ. Extracellular production of human parathyroid hormone as a thioredoxin fusion form in Escherichia coli by chemical permeabilization combined with heat treatment. Biotechnol Prog. 2005;21(5):1429–35.
pubmed: 16209546
doi: 10.1021/bp050137z
Liu Q, Lin J, Liu M, Tao X, Wei D, Ma X, et al. Large scale preparation of recombinant human parathyroid hormone 1–84 from Escherichia coli. Protein Expr Purif. 2007;54(2):212–9.
pubmed: 17449274
doi: 10.1016/j.pep.2007.03.009
Chen ZY, Cao J, Xie L, Li XF, Yu ZH, Tong WY. Construction of leaky strains and extracellular production of exogenous proteins in recombinant Escherichia coli. Microb Biotechnol. 2014;7(4):360–70.
pubmed: 24779863
pmcid: 4241728
doi: 10.1111/1751-7915.12127
Itakura K, Hirose T, Crea R, Riggs AD, Heyneker HL, Bolivar F, et al. Expression in Escherichia coli of a chemically synthesized gene for the hormone somatostatin. Science (1979). 1977;198(4321):1056–63.
Notani J, Saitoh Y, Terada M, Yamada H, Ishii Y, Satoh S, et al. High-level expression and efficient purification of recombinant somatostatin in Escherichia coli. Biotechnol Prog. 1989;5(1):40–5.
doi: 10.1002/btpr.5420050110
Maicas S, Moukadiri I, Nieto A, Valentín E. Construction of an expression vector for production and purification of human somatostatin in Escherichia coli. Mol Biotechnol. 2013;55(2):150–8.
pubmed: 23640683
doi: 10.1007/s12033-013-9667-3
Nespovitaya N, Barylyuk K, Eichmann C, Zenobi R, Riek R. The production of recombinant 15N, 13C-labelled somatostatin 14 for NMR spectroscopy. Protein Expr Purif. 2014;99:78–86.
pubmed: 24698890
doi: 10.1016/j.pep.2014.03.011
Jing XL, Luo XG, Tian WJ, Lv LH, Jiang Y, Wang N, et al. High-level expression of the antimicrobial peptide plectasin in Escherichia coli. Curr Microbiol. 2010;61(3):197–202.
pubmed: 20165851
doi: 10.1007/s00284-010-9596-3
Yang Y, Teng D, Zhang J, Tian Z, Wang S, Wang J. Characterization of recombinant plectasin: solubility, antimicrobial activity and factors that affect its activity. Process Biochem. 2011;46(5):1050–5.
doi: 10.1016/j.procbio.2011.01.018
Chen X, Wen Y, Li L, Shi J, Zhu Z, Luo Y, et al. The stability, and efficacy against penicillin-resistant Enterococcus faecium, of the plectasin peptide efficiently produced by Escherichia coli. J Microbiol Biotechnol. 2015;25(7):1007–14.
pubmed: 25791854
doi: 10.4014/jmb.1501.01056
Chen X, Shi J, Chen R, Wen Y, Shi Y, Zhu Z, et al. Molecular chaperones (TrxA, SUMO, Intein, and GST) mediating expression, purification, and antimicrobial activity assays of plectasin in Escherichia coli. Biotechnol Appl Biochem. 2015;62(5):606–14.
pubmed: 25311837
doi: 10.1002/bab.1303
Lv LH, Luo XG, Ni M, Jing XL, Wang N, Jiang Y, et al. Indipendent and tandem expression of a novel antimicrobial peptides plectasin in Escherichia coli. In: Advanced materials research. Trans Tech Publications Ltd; 2012. p. 134–8.
Marks CB, Vasser M, Ng P, Henzel W, Anderson S. Production of native, correctly folded bovine pancreatic trypsin inhibitor by Escherichia coli. J Biol Chem. 1986;261(16):7115–8.
pubmed: 2423515
doi: 10.1016/S0021-9258(17)38362-X
von Wilcken-Bergmann B, Tils D, Sartorius J, Auerswald EA, Schröder W, Müller-Hill B. A synthetic operon containing 14 bovine pancreatic trypsin inhibitor genes is expressed in E. coli. EMBO J. 1986;5(12):3219–25.
doi: 10.1002/j.1460-2075.1986.tb04632.x
Lauritzen C, Tüchsen E, Hansen PE, Skovgaard O. BPTI and N-terminal extended analogues generated by factor Xa cleavage and cathepsin C trimming of a fusion protein expressed in Escherichia coli. Protein Expr Purif. 1991;2(5–6):372–8.
pubmed: 1821811
doi: 10.1016/1046-5928(91)90096-2
Jose J, Zangen D. Autodisplay of the protease inhibitor aprotinin in Escherichia coli. Biochem Biophys Res Commun. 2005;333(4):1218–26.
pubmed: 15979569
doi: 10.1016/j.bbrc.2005.06.028
Meta A, Nakatake H, Imamura T, Nozaki C, Sugimura K. High-yield production and characterization of biologically active recombinant aprotinin expressed in Saccharomyces cerevisiae. Protein Expr Purif. 2009;66(1):22–7.
pubmed: 19233283
doi: 10.1016/j.pep.2009.02.005
Mairhofer J, Wittwer A, Cserjan-Puschmann M, Striedner G. Preventing T7 RNA polymerase read-through transcription—a synthetic termination signal capable of improving bioprocess stability. ACS Synth Biol. 2014;4:265–73.
pubmed: 24847676
doi: 10.1021/sb5000115
Egger E, Tauer C, Cserjan-Puschmann M, Grabherr R, Striedner G. Fast and antibiotic free genome integration into Escherichia coli chromosome. Sci Rep. 2020;10(1):16510.
pubmed: 33020519
pmcid: 7536200
doi: 10.1038/s41598-020-73348-x
Stirling CJ, Stewart G, Sherratt DJ. Multicopy plasmid stability in Escherichia coli requires host-encoded functions that lead to plasmid site-specific recombination. Mol Gen Genet. 1988;214(1):80–4.
pubmed: 3067082
doi: 10.1007/BF00340183
Schägger H. Tricine–SDS-PAGE. Nat Protoc. 2006;1(1):16–22.
pubmed: 17406207
doi: 10.1038/nprot.2006.4
Newton JM, Schofield D, Vlahopoulou J, Zhou Y. Detecting cell lysis using viscosity monitoring in E. coli fermentation to prevent product loss. Biotechnol Prog. 2016;32(4):1069–76.
pubmed: 27111912
pmcid: 4999026
doi: 10.1002/btpr.2292
Schimek C, Egger E, Tauer C, Striedner G, Brocard C, Cserjan-Puschmann M, et al. Extraction of recombinant periplasmic proteins under industrially relevant process conditions: selectivity and yield strongly depend on protein titer and methodology. Biotechnol Prog. 2020;36(5): e2999.
pubmed: 32259401
pmcid: 7685146
doi: 10.1002/btpr.2999